Summary of COVID-19 posaconazole studies

1. Prattes et al., Posaconazole for Prevention of COVID‐19‐Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case–Control Study (POSACOVID)

249 patient posaconazole prophylaxis study: 131% higher mortality (p<0.0001) and 54% improvement (p=0.41).
Prospective matched case-control study of 249 mechanically ventilated COVID-19 patients in Europe, showing variable impact of posaconazole prophylaxis on COVID-19-associated pulmonary aspergillosis (CAPA) incidence depending on baseline CAPA rates. Authors note: "Most of the currently available evidence on antifungal prophylaxis in critically ill COVID-19 patients is showing a reduction of CAPA rates (generally prevalence rates are given) but no significant difference in overall survival rates." Mortality results for this study are from the registry and are not reported in the paper.
Jan 2025, Mycoses, https://onlinelibrary.wiley.com/doi/10.1111/myc.70023, https://c19p.org/prattes

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0